Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development of a new disseminated intravascular coagulation score tailored for patients with chronic liver disease: a prospective observational study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Therapeutic targeting of fibrin-microglia interactions ameliorates Alzheimer's disease-related hyperexcitability and brain network dysfunction.

bioRxiv : the preprint server for biology·2026
Same author

Abdominal Fat Measures Are Associated With Sex-Specific Prothrombotic Changes in Middle-Aged Adults.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Rebalanced hemostasis, bleeding and thrombosis in liver disease: a comprehensive review of pathophysiology, management and future perspectives.

Seminars in thrombosis and hemostasis·2026
Same author

Prolonged Dual Hypothermic Oxygenated Machine Perfusion for Daytime Liver Transplant.

JAMA network open·2026
Same author

Visualization of intrahepatic activation of coagulation and its contribution to disease progression in mice with acetaminophen-induced acute liver injury.

Journal of thrombosis and haemostasis : JTH·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Aaron B Kantor1, Tanja A M Hoffman1, Dana Mannick2

  • 1Therini Bio, Sacramento, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

一个针对纤维素诱导炎症的新型抗体THN391在1a期研究中证明了安全性和耐受性. 它的长半衰期支持每月静脉注射用于神经退行性疾病的剂量.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经科学是一个神经科学.
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 目前的阿尔茨海默氏病 (AD) 治疗方法没有解决炎症,这是一个关键的疾病驱动因素,并带有安全风险,特别是在ApoE4同胞体.
  • THN391是一种新型单克隆抗体,向纤维素上的特定炎症表位,纤维素是一种参与血液凝结的蛋白质.
  • 这种表位被暴露在血管损伤的部位,并触发由微质和其他免疫细胞介导的炎症反应.

研究的目的:

  • 在健康人群中评估THN391的安全性,耐受性和药理动力学 (PK).
  • 评估THN391对凝血和纤维素分解的影响.
  • 为了确定未来临床试验的适当剂量方案.

主要方法:

  • 一个随机的,双盲的,安慰剂控制的第1a期试验,涉及健康志愿者的单次和多次上升剂量 (SAD和MAD).
  • 剂量范围从0.3到40.0毫克/公斤,与不同的管理频率 (Q2W和Q4W).
  • 安全性评估包括旋转性血栓凝结仪 (ROTEM) 来监测凝血和纤维素分解.

主要成果:

  • 在所有测试剂量中,THN391被发现是安全的,并且能很好地耐受,只有轻微的,与输液部位相关的不良事件.
  • 没有观察到实验室结果,生命体征或心电图的临床显著变化.
  • THN391没有影响凝血或纤维解,PK建模表明剂量相称性,终端半衰期为38天.

结论:

  • THN391是一种安全且耐受良好的第一类抗体,向纤维素诱导的炎症,支持每月IV剂量.
  • 计划在早期阿兹海默症患者中进行一项1b期研究,这些患者已确认患有大脑小血管疾病 (cSVD),其中包括ApoE4类同位素.
  • 即将进行的研究将使用生物标志物,MRI和认知评估来评估安全性,PK和初步疗效.